Claim 1: an Antibody that binds to Human csf-1r, where the Antibody is administered in combination with an Antibody that binds to Human pd-l1, for use in the treatment of cancer, for use in the Prevention or treatment of metastases, for use in the treatment of disease. Des inflammatory, for use in the treatment of bone loss.For use in the Treatment or delay the Progress of a disease of immune status or tumor immunity, for example for use in the stimulation of an immune response or function, for example the activity of t cells, the Antibody that binds to Human csf-1r,Used in combination therapy is characterized because it contains (a) a variable domain of heavy chain of SEQ ID no. 23 VH and VL light chain variable domain of SEQ ID no. 24 or (b) a variable domain of heavy chain of SEQ ID no. 31 VH and VL light chain variable domain of seq ID no. 32 (c) or a variable domain of heavy chain VH of SEQ ID no. 39 of L chain and a variable domainLightweight VL or SEQ ID no. 40 (d) a variable domain of heavy chain of SEQ ID no. 47 VH and VL light chain variable domain of SEQ ID no. 48) and a variable domain of heavy chain of SEQ ID no. 55 VH and VL light chain variable domain of SEQ ID no. 56； and the Antibody.That binds to Human pd-l1 used in combination therapy is characterized because it contains (a) a variable domain of heavy chain of SEQ ID no. 89 VH and VL light chain variable domain of SEQ ID no. 92 or (b) a variable domain of heavy chain VH of SEQ ID no. 90 and a variable domain Light chain VL of SEQ ID no. 93； or (c) a variable domain of heavy chain VH of SEQ ID no. 90 and a dLight chain variable ominio VL or SEQ ID no. 94 (d) a variable domain of heavy chain of SEQ ID no. 90 VH and VL light chain variable domain of SEQ ID no. 95) and a variable domain of heavy chain of SEQ ID no. 90 VH and VL light chain variable domain of SEQ ID no. 96 or (F) A Long Chain variable Domain SEQ ID no. 90 of VH and VL of light chain variable domain (SEQD no. 97 (g) or a variable domain
